Century Therapeutics Inc.

0.58
0.02 (4.50%)
At close: Mar 24, 2025, 3:59 PM
0.58
0.52%
After-hours: Mar 24, 2025, 07:32 PM EDT
4.50%
Bid 0.58
Market Cap 49.66M
Revenue (ttm) 7.12M
Net Income (ttm) -136.84M
EPS (ttm) -1.61
PE Ratio (ttm) -0.36
Forward PE -0.46
Analyst Buy
Ask 0.6
Volume 626,505
Avg. Volume (20D) 486,658
Open 0.57
Previous Close 0.56
Day's Range 0.56 - 0.59
52-Week Range 0.52 - 4.50
Beta 1.75

About IPSC

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting C...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 18, 2021
Employees 140
Stock Exchange NASDAQ
Ticker Symbol IPSC
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for IPSC stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 766.40% from the latest price.

Stock Forecasts

Earnings Surprise

Century Therapeutics has released their quartely earnings on Mar 19, 2025:
  • Revenue of $4.17M exceeds estimates by $3.2M, with 1457.09% YoY growth.
  • EPS of -0.43 exceeds estimates by 0.01, with 33.85% YoY growth.
  • Next Earnings Release

    Century Therapeutics Inc. is scheduled to release its earnings on May 8, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription